PDCD1 and nasopharyngeal carcinoma: Monoclonal antibodies targeting PD-1, including toripalimab, tislelizumab, penpulimab, pembrolizumab, and nivolumab, are currently used to treat advanced NPC, either in combination with chemotherapy as first-line therapy or as monotherapy following platinum-based chemotherapy [31].